AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01346163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF 03654746
Description: All participants will receive 3 weeks of PF-03654746 and 3 weeks of placebo. PF-03654746 and placebo will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.
Study NCT01346163 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be used as a comparator to the active arm.
Study NCT02349893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA treatment
Description: RFA treatment using CelonProSleep plus system
Study NCT03252964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor (CGM)
Description: Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
Study NCT03252964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity Tracker
Description: Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
Study NCT03252964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
Study NCT03401112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMR-687
Description: Oral administration of IMR-687 once daily with or without HU.
Study NCT03401112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of placebo once daily with or without HU.
Study NCT03706989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG samples will be recorded before and during the cardiac surgery in order to perform spectral and coherence analyses
Study NCT03706989 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Apolipoprotein genotype
Description: APOE genotyping will be performed for each patient
Study NCT03706989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Serum NfL measurements
Description: 5 perioperative blood samples will be taken to measure the evolution of NfL in the serum (before and until postoperative day 5)
Study NCT03706989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative neurocognitive evaluation
Description: Each patient will benefit from a complete neurocognitive evaluation before surgery (battery of validated cognitive tests)
Study NCT00482521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-4047
Description: Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period. Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.
Study NCT02458638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Description: Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.
Study NCT02091882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral placebo-embedded IEM tablet.
Study NCT02091882 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination product of Aripiprazole + IEM + Sensor + MIND1 Application
Description: Combination product of aripiprazole tablet embedded with sensor and wearable patch with MIND1 system on smartphone
Study NCT01027780 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction
Description: The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
Study NCT03199274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yttrium-90 Microsphere Radioembolization
Description: Undergo standard of care Y-90 radioembolization
Study NCT03199274 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Yttrium-90 Microsphere Radioembolization
Description: Undergo standard of care Y-90 radioembolization
Study NCT03199274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Protein-Type A Microspheres
Description: Given IV.
Study NCT03199274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Ultrasound Imaging
Description: Undergo CEUS
Study NCT05046548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine for intramuscular injection
Description: Volunteers (10 at the Stage 1; 140 at the Stage 2; 150 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
Study NCT05046548 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator (without active ingredient) for intramuscular injection
Description: Volunteers (5 at the Stage 1; 45 at the Stage 2; 50 at the Stage 3) will receive the vaccine twice spaced 14 days apart, intramuscularly, at a dose of 0.5 ml
Study NCT02304809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase. Mutations in the BRAF gene which substitute the valine at amino acid position 600 result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation
Study NCT00115882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI + CBST
Description: The HS Study intervention consisted of proactive identification and recruitment of eligible smokers (and selected nonsmokers) within the target population, and a protocol-guided series of counselor-initiated, personally-tailored telephone calls (from 1 to 10, depending on participant's interest) to eligible high school senior smokers and nonsmokers in experimental high schools. The telephone-delivered behavioral intervention integrated Motivational Interviewing and Cognitive Behavioral Skills building. Content and dose were tailored to the individual.
Study NCT01416766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring-nurse-primary care provider feedback loop
Description: Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer. They will be encouraged to upload readings at least once/month. Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.
Study NCT03461354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MucoLox
Description: MucoLox formulation, with MucoLox as the delivery vehicle, combined with preserved water, beta-glucan, dexpanthenol, and glutamine
Study NCT03461354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: Sodium bicarbonate oral rinse
Study NCT01297036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil, ODT 10 mg
Description: Test- Donepezil Hydrochloride 10 mg Tablet single dose
Study NCT01297036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil, 10 mg tablet
Description: Reference: Donepezil Hydrochloride 10 mg Tablet
Study NCT01345045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-639
Description: ABT-639 Twice Daily for six weeks.
Study NCT01345045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: pregabalin starting dose twice daily for 1 week then titrated to maintenance dose twice daily for the remainder of the study.
Study NCT01345045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 6 weeks.
Study NCT03651765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Once daily subcutaneous injection
Study NCT03364647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm A - blood flow restriction training
Description: Group receive standard of care plus blood flow restriction training
Study NCT03364647 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Arm B - standard of care
Description: Group will receive standard of care plus a sham version of blood flow restriction training
Study NCT00551499 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT + AOP
Description: The CSA group will undergo 2 sleep evaluation on two consecutive nights, during which the device will be programmed according to the randomization scheme (one night CRT, DDD/45 and the other CRT, DDD/15 bpm over mean nocturnal heart rate). The mean nocturnal heart rate over the last week is derived from the device memory.
Study NCT02735174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor cap system for inhalers
Description: All subjects will be given a commercially available inhaler cap with monitoring sensor on clinically prescribed asthma inhalers.
Study NCT02735174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App for SmartPhone
Description: All subjects will be given smart phone with mobile software management platform to motivate and record medication adherence.
Study NCT02735174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviews
Description: All subjects will have motivational telehealth visits to assess adherence and promote problem-solving skills
Study NCT02735174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth clinic visits
Description: All subjects will have asthma medical visits via telehealth technology to assess asthma control.
Study NCT01706471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus + Low dose CsA +PD
Description: Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up >3 ng/mL. Steroid dose follows local protocol.
Study NCT01706471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myfortic+ Standard CsA + PD
Description: Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
Study NCT02706236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pancrelipase
Description: Oral Pancrelipase, 720,000 units spread throughout the day with meals and snacks, taken daily PO for 4 weeks
Study NCT02706236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will consist of lactose, spread throughout the day with meals and snacks, taken daily PO for 4 weeks
Study NCT02556944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with multifocal intraocular lens
Description: Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.
Study NCT02689297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: chlorine dioxide
Description: First week, subjects were instructed to do regular tooth brushing. After that group A was requested to use chlorine dioxide mouthwash two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
Study NCT02689297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: small toothbrush for tongue cleaning
Description: First week, subjects were instructed to do regular tooth brushing. After that group B was requested to brush their tongue with small toothbrush two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
Study NCT04493723 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: To collect tumour tissue
Study NCT04493723 — intervention group
Intervention type: PROCEDURE
Intervention: Venepuncture
Description: To collect blood samples
Study NCT02936856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepatic Arteriography
Study NCT02936856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic Arteriography
Study NCT04347746 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: stretching physiotherapy
Description: A booklet with images and a description of all movements to be performed during therapy will be offered to patients. The booklet illustrates the movements for stretching the upper limbs divided as follows: three movements for the neck, three movements for the arms and forearms and four movements for the hands.~The therapy will be carried out twice a week at the Unopar research center, under the guidance of a physiotherapist trained in technique and supervision by a senior therapist. At the end of each movement, the individual is instructed to maintain the position for 40 seconds.~Patients will be instructed to appear in comfortable clothes and the environment will have favorable conditions.
Study NCT04347746 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial therapy
Description: Myofascial therapy will be performed on the upper limbs, pectoral and dorsal regions with the aid of hooks (instrument assisted soft-tissue mobilization). In the supine position, the pectoral muscles will be manipulated (infracromial, external, axillary-claviculopectoral fossa), biceps brachii (short head, long and forearm insertion), round pronator, anterior forearm musculature (compartment of the radial extensor of the long carpus and brevis, finger extensor and ulnar carpal extensor). In lateral decubitus the deltoid muscle in the anterior, middle and posterior portions. In the prone position, the trapezius muscle (in its cervical, scapular and nuchal insertions), scapular levator muscle, great dorsal muscle (in its lateral insertions) and triceps brachii muscle. The hook manipulation time is two minutes of execution for each muscle mentioned above, making a total time of each section of forty minutes. There will be two weekly sessions with an interval between forty-eight hours.
Study NCT02777060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Subjects will perform progressive and computerized foot and ankle exercises which include weight shifting, ankle reaching task while standing, and virtual obstacle crossing task (i.e. balancing on single leg) using wearable sensors technology (Exergaming) equipment). Subjects will perform these exercises for 4-6 weeks, twice per week. The duration of exercise per session is anticipated to be 30-45 minutes.
Study NCT02777060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home based balance training
Description: Subjects in the control group will ask to perform a standard home based balance program for 4-6 weeks. The home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback and Exergaming equipment.
Study NCT00637299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active osteopathic treatment (OMT+PR): Active Comparator
Description: The treatment was done once a week for 4 weeks and lasted 30 minutes.The examination was done according to the following scheme: anamnesis; physical examination (evaluation of the posture, palpation, tests for passive and active motion of areas linked to altered respiratory function); cranic-sacral evaluation (by means of a palpation of the cranic-sacral mechanism).
Study NCT00637299 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham osteopathic treatment (SOT+PR)
Description: Only soft manipulation was performed
Study NCT03741348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: In (ES) group After skin sterilization, ESPB was performed in sitting position at the level of T9 linear ultrasound (US) transducer (Phillips-Saronno Italy) was placed vertically 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between the two transverse processes. After local infiltration of needle insertion site with 2-3ml of 2% lidocaine, a 22-gauge Short bevel needle (Spinocan, B.Braun Melsungen AG, Germany) was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles. Then, up to 20 ml of bupivacaine 0.5% was injected. The procedure was repeated following the same steps on the other side of back.
Study NCT03741348 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: in control group, Erector Spinae Plane Block will not be done
Study NCT03773848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction Internal Fixation (ORIF)
Description: Open Reduction Internal Fixation (ORIF) of fracture lateral third clavicle by hook plate \& tightrope
Study NCT00927992 — intervention group
Intervention type: OTHER
Intervention: Epidemiological Non interventional
Description: Epidemiological Non interventional
Study NCT02648607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customised Dynamic Elastomeric Fabric Orthosis (DEFO)
Description: Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthosis (DEFO). Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
Study NCT04351204 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiotherapy
Description: multiple new techniques and software for MR-guided adaptive radiation therapy.
Study NCT00909493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Network Access
Description: Primary Care Physicians in this treatment group will have access to a pain specialist at the Pain Management Unit.
Study NCT01190748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine 4 mg Tablet, single dose
Description: A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fasting conditions
Study NCT01190748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reminyl 4 mg Tablet, single dose
Description: B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fasting conditions
Study NCT03509103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Partograph
Description: The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely.
Study NCT03509103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Partograph
Description: The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely.
Study NCT01561274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 ml bupivacaine
Description: 2 ml bupivacaine
Study NCT01561274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5 ml bupivicaine.
Description: 1.5 ml bupivicaine.
Study NCT04094844 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wearable activity sensor
Description: Caregivers and patients in both arms of the study will have a Fitbit wearable activity sensor to track activity and sleep.